For the year ending 2025-12-31, ZURA had -$67,091K decrease in cash & cash equivalents over the period. -$64,928K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss before redeemable noncontrolling interest | -68,650 |
| Share-based compensation expense | 12,332 |
| Depreciation and amortization | 49 |
| Foreign exchange transaction gain | -84 |
| Gain on extinguishment of baffx17 liability | 5,000 |
| Other non-cash items, net | -4 |
| Prepaid expenses and other current assets | 657 |
| Other assets | 814 |
| Accounts payable and accrued expenses | -2,163 |
| Net cash used in operating activities | -64,815 |
| Purchase of fixed assets | 113 |
| Net cash used in investing activities | -113 |
| Proceeds from issuance of class a ordinary shares in connection with a sale under the atm, net of 0.2 million of commissions | 5,093 |
| Issuance of class a ordinary shares upon exercise of pre-funded warrants | 3 |
| Proceeds from exercise of stock options | 107 |
| Restricted stock units withheld to pay employee withholding taxes | 41 |
| Consideration paid for athanor agreement | 7,325 |
| Net cash provided by (used in) financing activities | -2,163 |
| Net increase in cash and cash equivalents | -67,091 |
| Cash and cash equivalents, beginning of period | 176,498 |
| Cash and cash equivalents, ending of period | 109,407 |
Zura Bio Ltd (ZURA)
Zura Bio Ltd (ZURA)